<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0802221694
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EDARBI 80 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZILSARTAN MEDOXOMIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        97.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Arab Pharmaceutical Manufacturing" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Arab Pharmaceutical Manufacturing
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Edarbi contains an active substance called azilsartan medoxomil and belongs to a class of medicines called angiotensin II receptor antagonists (AIIRAs). Angiotensin II is a substance which occurs naturally in the body and which causes the blood vessels to tighten, therefore increasing your blood pressure. Edarbi blocks this effect so that the blood vessels relax, which helps lower your blood pressure.</p><p>This medicine is used for treating high blood pressure (essential hypertension) in adult patients (over 18 years of age).</p><p>A reduction in your blood pressure will be measureable within 2 weeks of initiation of treatment and the full effect of your dose will be observed by 4 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Edarbi if you </strong></p><ul><li>Are allergic to azilsartan medoxomil or any of the other ingredients of this medicine (listed in section 6).</li><li>Are more than 3 months pregnant. (It is also better to avoid this medicine in early pregnancy - see pregnancy section).</li><li>Have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</li></ul><p><strong>&nbsp;Warnings and Precautions </strong></p><p>Talk to your doctor before taking Edarbi, especially if you</p><ul><li>Have kidney problems.</li><li>Are on dialysis or had a recent kidney transplant.</li><li>Have severe liver disease.</li><li>Have heart problems (including heart failure, recent heart attack).</li><li>Have ever had a stroke.</li><li>Have low blood pressure or feel dizzy or lightheaded.</li><li>Are vomiting, have recently had severe vomiting, or have diarrhoea.</li><li>Have raised levels of potassium in your blood (as shown in blood tests).</li><li>Have a disease of the adrenal gland called primary hyperaldosteronism.</li><li>Have been told that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral valve stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called &ldquo;obstructive hypertrophic cardiomyopathy&rdquo;).</li><li>Are taking any of the following medicines used to treat high blood pressure:</li></ul><p>-&nbsp;An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>- Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Edarbi&rdquo;.</p><p>You must tell your doctor if you think you are (or might become) pregnant. Edarbi is not recommended in early pregnancy, and must NOT be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see section &quot;Pregnancy section and breast-feeding&quot;). Edarbi may be less effective in lowering the blood pressure in black patients.</p><p><strong>Children and adolescents</strong></p><p>There is limited data on the use of Edarbi in children or adolescents under 18 years of age. Therefore, this medicine should not be given to children or adolescents.</p><p><strong>&nbsp;Other medicines and Edarbi</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Edarbi can affect the way some other medicines work, and some medicines can have an effect on Edarbi.</p><p>In particular, tell your doctor if you are taking any of the following medicines:</p><ul><li>Lithium (a medicine for mental health problems)</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib (medicines to relieve pain and inflammation)</li><li>Acetylsalicyclic acid if taking more than 3 g per day (medicine to relieve pain and inflammation)</li><li>Medicines that increase the amount of potassium in your blood; these include potassium supplements, potassium-sparing medicines (certain &lsquo;water tablets&rsquo;) or salt substitutes containing potassium</li><li>Heparin (a medicine for thinning the blood)</li><li>Diuretics (water tablets)</li><li>Aliskiren or other medicines to lower your blood pressure (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, such as enalapril, lisinopril, ramipril or valsartan, telmisartan, irbesartan).</li></ul><p>Your doctor may need to change your dose and/or to take other precautions if you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Edarbi&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p><strong>Pregnancy and breast-feeding </strong></p><p><em>Pregnancy </em></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Edarbi.</p><p>Edarbi is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><em>Breast-feeding </em></p><p>Tell your doctor if you are breast-feeding. Edarbi is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines </strong></p><p>Edarbi is unlikely to have an effect on driving or using machines. However, some people may feel tired or dizzy when taking this medicine and if this happens to you, do not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. It is important to keep taking Edarbi every day at the same time.</p><p>Edarbi is for oral use. Take the tablet with plenty of water.</p><p>You can take this medicine with or without food.</p><ul><li>The usual starting dose is 40 mg once a day. Your doctor may increase this dose to a maximum of 80 mg once a day depending on blood pressure response.</li><li>For patients such as the very elderly (75 years and above) your doctor may recommend a lower starting dose of 20 mg once a day.</li><li>If you suffer from mild or moderate liver disease your doctor may recommend a lower starting dose of 20 mg once a day.</li><li>For patients who recently have lost body fluids e.g. through vomiting or diarrhoea, or by taking water tablets, your doctor may recommend a lower starting dose of 20 mg once a day.</li><li>If you suffer from other coexisting illnesses such as severe kidney disease or heart failure your doctor will decide on the most appropriate starting dose.</li></ul><p><strong>If you take more Edarbi<strong> </strong>than you should</strong></p><p>If you take too many tablets, or if someone else takes your medicine, contact your doctor immediately. You may feel faint or dizzy if you have taken more than you should.</p><p><strong>&nbsp;If you forget to take Edarbi</strong></p><p>Do not take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.</p><p><strong>If you stop taking Edarbi</strong></p><p>If you stop taking Edarbi, your blood pressure may increase again. Therefore, do not stop taking Edarbi without first talking to your doctor about alternative treatment options.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking Edarbi and seek medical help immediately if you have any of the following allergic reactions, which occur rarely (may affect up to 1 in 1,000 people): </strong></p><ul><li>Difficulties in breathing, or swallowing, or swelling of the face, lips, tongue and/or throat (angioedema)</li><li>Itching of the skin with raised lumps.</li></ul><p><strong><em>Other possible side effects include: </em></strong></p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><ul><li>Dizziness</li><li>Diarrhoea</li><li>Increased blood creatine phosphokinase (an indicator of muscle damage).</li></ul><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><ul><li>Low blood pressure, which may make you feel faint or dizzy</li><li>Feeling tired</li><li>Swelling of the hands, ankles or feet (peripheral oedema)</li><li>Skin rash and itching</li><li>Nausea</li><li>Muscle spasms</li><li>Increased serum creatinine in the blood (an indicator of kidney function)</li><li>Increased uric acid in the blood.</li></ul><p><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><ul><li>Changes in blood test results including decreased levels of a protein in the red blood cells (haemoglobin).</li></ul><p>When Edarbi is taken with chlortalidone (a water tablet), higher levels of certain chemicals in the blood (such as creatinine), which are indicators of kidney function, have been seen commonly (in less than 1 in 10 users), and low blood pressure is also common.</p><p>Swelling of the hands, ankles or feet is more common (in less than 1 in 10 users) when Edarbi is taken with amlodipine (a calcium channel blocker for treating hypertension) than when Edarbi is taken alone (less than 1 in 100 users). The frequency of this effect is highest when amlodipine is taken alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is azilsartan medoxomil (as potassium).</p><p>Each 40 mg tablet contains azilsartan medoxomil potassium equivalent to 40 mg azilsartan medoxomil.</p><p>Each 80 mg tablet contains azilsartan medoxomil potassium equivalent to 80 mg azilsartan medoxomil.</p><p>The other ingredients are mannitol, fumaric acid, sodium hydroxide, hydroxypropylcellulose, croscarmellose sodium, microcrystalline cellulose and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Edarbi 40 mg Tablets are white round tablets debossed with “ASL” on one side and “40” on the other side in aluminum blisters.

Edarbi 80 mg Tablets are white round tablets debossed with “ASL” on one side and “80” on the other side in aluminum blisters.

Pack size: 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: jpimedical@hikma.com</p><p><strong>Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC.</p><p>P.O. Box 42</p><p>Sult, Jordan</p><p>Tel: + (962-5)3492200</p><p>Fax: + (962-5)3492203</p><p><strong>Under licensed from</strong></p><p>Takeda Pharmaceuticals International AG,</p><p>Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2020; version number SA2.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ايداربي على المادة الفعّالة التي تعرف بأزيلسارتان ميدوكسوميل التي تنتمي إلى فئة الأدوية التي تعرف باسم مضادات مستقبلات الأنجيوتنسين-II. الأنجيوتنسين-II هو عبارة عن مادة توجد بصورة طبيعية في الجسم وتسبب تضيق الأوعية الدموية، وبالتالي ارتفاع ضغط الدم لديك. يمنع ايداربي هذا التأثير مما يؤدي إلى ارتخاء الأوعية الدموية، مما يساعد على خفض ضغط الدم لديك.</p><p dir="RTL">يستخدم هذا الدواء لعلاج ضغط الدم المرتفع (ارتفاع ضغط الدم الأساسي) في المرضى البالغين (بعمر فوق 18 عاماً).</p><p dir="RTL">يمكنك ملاحظة انخفاض ضغط الدم لديك خلال أسبوعين من بدء العلاج ويتم ملاحظة التأثير الكامل لجرعتك بعد مرور 4 أسابيع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ايداربي</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لأزيلسارتان ميدوكسوميل أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت حاملاً منذ أكثر من ثلاثة أشهر. (يفضل أيضاً تجنب تناول هذا الدواء في المرحلة الأولى من الحمل - راجعي قسم الحمل).</li><li>إذا كنت تعاني من مرض السكري أو من قصور في وظائف الكلى ويتم علاجك باستخدام دواء خافض لضغط الدم الذي يحتوي على أليسكيرين.</li></ul><p dir="RTL"><strong>&nbsp;الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك قبل استخدام ايداربي، خاصة:</p><ul dir="rtl"><li>إذا كنت تعاني من مشكلات في الكلى.</li><li>إذا كنت تخضع لغسيل الكلى أو خضعت مؤخراً لعملية زرع كلى.</li><li>إذا كنت تعاني من مرض حاد في الكبد.</li><li>إذا كنت تعاني من مشكلات في القلب (بما في ذلك فشل القلب، أزمة قلبية حديثة).</li><li>إذا عانيت مسبقاً من سكتة دماغية.</li><li>إذا كنت تعاني من انخفاض ضغط الدم أو تشعر بالدوخة أو الدوار.</li><li>إذا كنت تعاني من القيء، أو عانيت مؤخراً من قيء شديد، أو كنت مصاباً بالإسهال.</li><li>إذا كنت تعاني من ارتفاع مستويات البوتاسيوم في الدم (كما يتضح من اختبارات الدم).</li><li>إذا كنت تعاني من مرض في الغدة الكظرية يسمى فرط الألدوستيرونية الأولي.</li><li>إذا قيل لك أنك تعاني من تضيق في صمامات قلبك (يسمى &quot;تضيق الصمام الأبهري أو التاجي&quot;) أو أن سمك عضلة القلب لديك متزايد على نحو غير طبيعي (يسمى &quot;اعتلال عضلة القلب الضخامي الانسدادي&quot;).</li><li>إذا كنت تتناول أي من الأدوية التالية المستخدمة لعلاج ضغط الدم المرتفع:</li></ul><p dir="RTL">- مثبط الإنزيم المحول للأنجيوتنسين (على سبيل المثال: إينالابريل، لايسينوبريل، راميبريل)، خاصة إذا كنت تعاني من مشكلات في الكلى متعلقة بمرض السكري.</p><p dir="RTL">- أليسكيرين.</p><p dir="RTL">يمكن أن يتحقق طبيبك من وظائف الكلى لديك، ضغط دمك، ومستوى الكهارل (على سبيل المثال البوتاسيوم) في دمك على فترات زمنية منتظمة.</p><p dir="RTL">اطلع أيضاً على المعلومات الموجودة تحت العنوان &quot;لا تستخدم ايداربي&quot;.</p><p dir="RTL">يجب إبلاغ الطبيب إذا كنت تعتقدين بأنك حاملاً (أو قد تصبحين) حاملاً. لا يوصى باستخدام دواء ايداربي في شهور الحمل الأولى، ولا يجب تناوله إذا كنت حاملاً منذ أكثر من ثلاثة أشهر، لأنه قد يسبب ضرراً بالغاً لطفلك في حال استخدامه في هذه المرحلة (انظري قسم &quot;الحمل والرضاعة&quot;). قد يكون ايداربي أقل فعالية في خفض ضغط الدم في المرضى ذوي البشرة السوداء.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تتوفر بيانات محدودة حول استخدام ايداربي في الأطفال أو المراهقين الذين تقل أعمارهم عن 18 عاماً. لذلك، يجب عدم إعطاء هذا الدواء للأطفال أو المراهقين.</p><p dir="RTL"><strong>&nbsp;الأدوية الأخرى وايداربي</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL">يمكن أن يؤثر ايداربي على مفعول الأدوية الأخرى، كما أنه يمكن لبعض الأدوية أن تؤثر على مفعول دواء ايداربي.</p><p dir="RTL">أبلغ الطبيب إذا كنت تتناول أيّاً من الأدوية التالية على وجه الخصوص:</p><ul dir="rtl"><li>الليثيوم (دواء لعلاج مشكلات الصحة النفسية)</li><li>مضادات الالتهاب غير الستيرويدية، مثل إيبوبروفين أو ديكلوفيناك أو سيليكوكسيب (أدوية لتخفيف الألم والالتهاب)</li><li>حمض الأسيتيل ساليسيليك في حالة تناول أكثر من 3 غم يومياً (دواء لتخفيف الألم والالتهاب)</li><li>الأدوية التي تعمل على زيادة كمية البوتاسيوم في الدم؛ وتشمل مكملات البوتاسيوم أو الأدوية الموفرة للبوتاسيوم (ادوية معينة من مدرات البول) أو بدائل الملح المحتوية على البوتاسيوم.</li><li>الهيبارين (دواء لترقيق الدم)</li><li>مدرات البول&nbsp;</li><li>أليسكيرين أو الأدوية الأخرى التي تعمل على خفض ضغط الدم لديك (مثبط الإنزيم المحول للأنجيوتنسين، أو حاصر مستقبل أنجيوتنسين II، مثل إينلابريل، لايسينوبريل، وراميبريل، أو فالسارتان، تلميسارتان، وإربيسارتان).</li></ul><p dir="RTL">قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى إذا كنت تتناول دواء مثبط للإنزيم المحول للأنجيوتنسين أو أليسكيرين (انظر أيضاً الأقسام &quot;لا تستخدم ايداربي&quot; و&quot;الاحتياطات والتحذيرات&quot;).</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL"><em>الحمل </em>&nbsp;</p><p dir="RTL">يجب إبلاغ الطبيب إذا كنت تعتقدين بأنك حاملاً أو (قد تصبحين) حاملاً. سينصحك طبيبك عادة بالتوقف عن تناول هذا الدواء قبل أن تصبحي حاملاً أو بمجرد معرفتك بأنك حامل وسينصحك بتناول دواء آخر بدلاً من ايداربي.</p><p dir="RTL">لا يوصى باستخدام دواء ايداربي في شهور الحمل الأولى، ولا يجب تناوله إذا كنت حاملاً منذ أكثر من ثلاثة أشهر. قد يسبب ايداربي حدوث ضرراً بالغاً لطفلك إذا استخدمتِ العلاج بعد الشهر الثالث من الحمل.</p><p dir="RTL"><em>الرضاعة الطبيعية </em></p><p dir="RTL">أخبري طبيبك إذا كنتِ ترضعين رضاعة طبيعية. لا يوصى باستخدام دواء ايداربي للأمهات اللائي يرضعن رضاعة طبيعية، وقد يختار طبيبك علاجاً آخراً لك إذا كنت ترغبين بتقديم الرضاعة الطبيعية، وخاصةً إذا كان طفلك حديث الولادة أو كان مولوداً قبل موعد ولادته.</p><p dir="RTL"><strong>تأثير ايداربي على القيادة واستخدام الآلات </strong></p><p dir="RTL">من غير المرجح أن يكون لايداربي تأثير على القيادة أو استخدام الآلات. مع ذلك، قد يشعر بعض الأشخاص بالتعب أو الدوخة عند تناول هذا الدواء، وإذا حدث ذلك لك، تجنب القيادة أو استعمال أي أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما وصفه لك الطبيب تماماً. تأكد من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات. من المهم الحفاظ على تناول ايداربي يومياً في نفس الوقت.</p><p dir="RTL">يؤخذ ايداربي عن طريق الفم. يجب أخذ القرص مع كمية وفيرة من الماء.</p><p dir="RTL">يمكنك تناول هذا الدواء مع أو بدون الطعام.</p><ul dir="rtl"><li>الجرعة الابتدائية الاعتيادية هي 40 ملغم مرة واحدة يومياً. قد يقوم طبيبك بزيادة هذه الجرعة إلى 80 ملغم بحد أقصى مرة واحدة يومياً تبعاً لاستجابة ضغط الدم لديك.</li><li>للمرضى مثل كبار السن جداً (75 عاماً فأكثر)، قد يوصي طبيبك بجرعة بداية منخفضة تبلغ 20 ملغم مرة واحدة يومياً.</li><li>إذا كنت تعاني من مرض بسيط إلى معتدل في الكبد، قد يوصي طبيبك بجرعة بداية منخفضة تبلغ 20 ملغم مرة واحدة يومياً.</li><li>للمرضى الذين تعرضوا مؤخراً لفقدان سوائل الجسم، عن طريق القيء أو الإسهال مثلاً، أو من خلال تناول مدرات البول، قد يوصي طبيبك بجرعة بداية منخفضة تبلغ 20 ملغم مرة واحدة يومياً.</li><li>إذا كنت تعاني من أمراض مزمنة أخرى مثل مرض شديد في الكلى أو فشل القلب، سيقرر طبيبك جرعة البداية الأكثر ملائمة لك.</li></ul><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ايداربي</strong></p><p dir="RTL">إذا تناولت الكثير من الأقراص، أو إذا تناول شخص آخر دوائك، فاتصل بطبيبك على الفور. قد تشعر بالإغماء أو بالدوار إذا تناولت جرعة زائدة.</p><p dir="RTL"><strong>&nbsp;إذا نسيت تناول ايداربي</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. فقط تناول جرعتك التالية في الوقت المعتاد.</p><p dir="RTL"><strong>إذا توقفت عن تناول ايداربي</strong></p><p dir="RTL">إذا توقفت عن تناول دواء ايداربي، فقد يرتفع ضغط الدم لديك مرة أخرى. لذلك لا تتوقف عن تناول ايداربي بدون استشارة طبيبك أولاً حول الخيارات العلاجية البديلة.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>توقف عن تناول ايداربي واطلب المساعدة الطبية على الفور إذا تعرضت لأي من ردود الفعل التحسسية التالية، والتي نادراً ما تحدث (</strong><strong>قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>1000 </strong><strong>شخص</strong><strong>): </strong></p><ul dir="rtl"><li>صعوبات في التنفس أو البلع، أو تورم الوجه و/أو الشفتين و/أو اللسان و/أو الحلق (الوذمة الوعائية)</li><li>حكة بالجلد مع وجود كتل متورمة.</li></ul><p dir="RTL"><strong><em>تتضمن الآثار الجانبية المحتملة الأخرى على</em></strong><strong><em>: </em></strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong><strong>(</strong><strong>قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>10 </strong><strong>أشخاص</strong><strong>): </strong></p><ul dir="rtl"><li>دوخة</li><li>إسهال</li><li>زيادة مستوى فوسفوكيناز الكرياتين في الدم (إشارة إلى الإصابة بتلف العضلات).</li></ul><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (</strong><strong>قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>100&nbsp;</strong><strong>شخص</strong><strong>): </strong></p><ul dir="rtl"><li>انخفاض ضغط الدم، مما قد يشعرك بالإغماء أو الدوار</li><li>الشعور بالتعب</li><li>تورم اليدين أو الكاحلين أو القدم (الوذمة المحيطية)</li><li>الطفح الجلدي والحكة</li><li>الغثيان</li><li>تشنجات عضليةة</li><li>زيادة في كرياتينين الدم (مؤشر على وظائف الكلى)</li><li>ارتفاع مستوى حمض اليوريك في الدم.</li></ul><p dir="RTL"><strong>الآثار الجانبية النادرة (</strong><strong>قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>1000&nbsp;</strong><strong>شخص</strong><strong>): </strong></p><ul dir="rtl"><li>تغيرات في نتائج اختبارات الدم تشتمل على انخفاض مستويات بروتين معين موجود في خلايا الدم الحمراء (الهيموجلوبين).</li></ul><p dir="RTL">عند تناول ايداربي مع كلورتاليدون (مدر للبول)، شوهد بشكل شائع (في أقل من شخص واحد من كل 10 مستخدمين) ارتفاع مستويات بعض المواد الكيميائية المعينة في الدم (مثل الكرياتينين)، والتي تعد مؤشرات لوظائف الكلى، وكان انخفاض ضغط الدم شائعاً أيضاً.</p><p dir="RTL">يكون تورم اليدين أو الكاحلين أو القدم أكثر شيوعاً (في أقل من شخص واحد من كل 10 مستخدمين) عند تناول ايداربي مع أملوديبين (حاصر لقنوات الكالسيوم لعلاج ارتفاع ضغط الدم) منه عند تناول ايداربي بمفرده (أقل من شخص واحد في كل 100 مستخدم). يكون تكرار هذا التأثير في أعلى معدلاته عند تناول أملوديبين بمفرده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي أزيلسارتان ميدوكسوميل (على شكل بوتاسيوم).</p><p dir="RTL">يحتوي كل قرص من 40 ملغم على أزيلسارتان ميدوكسوميل البوتاسيوم يكافئ 40 ملغم أزيلسارتان ميدوكسوميل.</p><p dir="RTL">يحتوي كل قرص من 80 ملغم على أزيلسارتان ميدوكسوميل البوتاسيوم يكافئ 80 ملغم أزيلسارتان ميدوكسوميل.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول، حمض الفيوماريك، هيدروكسيد الصوديوم، هيدروكسي بروبيل السيلليلوز، كروسكارميللوز الصوديوم، سيلليلوز بلوري مكروي وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص ايداربي 40 ملغم هي أقراص بيضاء مستديرة محفور عليها &quot;ASL&quot; على أحد الجانبين و&quot;40&quot; على الجانب الآخر معبأة في أشرطة من الألمنيوم.</p><p dir="RTL" style="text-align:right">أقراص ايداربي 80 ملغم هي أقراص بيضاء مستديرة محفور عليها &quot;ASL&quot; على أحد الجانبين و&quot;80&quot; على الجانب الآخر معبأة في أشرطة من الألمنيوم.</p><p dir="RTL" style="text-align:right">حجم العبوة: 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: jpimedical@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p dir="RTL">صندوق بريد 42</p><p dir="RTL">السلط، الأردن<br />هاتف: 3492200 (5-962) +<br />فاكس: 3492203 (5-962) +</p><p dir="RTL"><strong>بترخيص من</strong></p><p dir="RTL">شركة تاكيدا الدوائية الدولية المحدودة،</p><p dir="RTL">سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2020/09؛ رقم النسخة SA2.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Edarbi 80 mg Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains azilsartan medoxomil potassium equivalent to 80 mg azilsartan medoxomil.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 

White round tablets debossed with “ASL” on one side and “80” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Edarbi is indicated for the treatment of essential hypertension in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended starting dose is 40 mg once daily. The dose may be increased to a maximum of 80 mg once daily for patients whose blood pressure is not adequately controlled at the lower dose.</p><p>Near-maximal antihypertensive effect is evident at 2 weeks, with maximal effects attained by 4 weeks.</p><p>If blood pressure is not adequately controlled with Edarbi alone, additional blood pressure reduction can be achieved when this treatment is coadministered with other antihypertensive medicinal products, including diuretics (such as chlortalidone and hydrochlorothiazide) and calcium channel blockers (see sections 4.3, 4.4, 4.5 and 5.1).</p><p><em><u>Special populations </u></em></p><p><em>Elderly (65 years and over) </em></p><p>No initial dose adjustment with Edarbi is necessary in elderly patients (see section 5.2), although consideration can be given to 20 mg as a starting dose in the very elderly (&ge; 75 years), who may be at risk of hypotension.</p><p><em>Renal impairment </em></p><p>Caution should be exercised in hypertensive patients with severe renal impairment and end stage renal disease as there is no experience of use of Edarbi in these patients (see sections 4.4 and 5.2).</p><p>Hemodialysis does not remove azilsartan from the systemic circulation.</p><p>No dose adjustment is required in patients with mild or moderate renal impairment.</p><p><em>&nbsp;Hepatic impairment </em></p><p>Edarbi has not been studied in patients with severe hepatic impairment and therefore its use is not recommended in this patient group (see sections 4.4 and 5.2).</p><p>As there is limited experience of use of Edarbi in patients with mild to moderate hepatic impairment close monitoring is recommended and consideration should be given to 20 mg as a starting dose (see section 5.2).</p><p><em>Intravascular volume depletion </em></p><p>For patients with possible depletion of intravascular volume or salt depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics), Edarbi should be initiated under close medical supervision and consideration can be given to 20 mg as a starting dose (see section 4.4).</p><p><em>&nbsp;Black population </em></p><p>No dose adjustment is required in the black population, although smaller reductions in blood pressure are observed compared with a non-black population (see section 5.1). This generally has been true for other angiotensin II receptor (AT1) antagonists and angiotensin-converting enzyme inhibitors.</p><p>&nbsp;Consequently, uptitration of Edarbi and concomitant therapy may be needed more frequently for blood pressure control in black patients.</p><p><em>Paediatric population </em></p><p>The safety and efficacy of Edarbi in children and adolescents aged 0 to &lt; 18 years have not yet been established.</p><p>No data are available.</p><p><u>Method of administration</u></p><p>Edarbi is for oral use and may be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
• Second and third trimester of pregnancy (see sections 4.4 and 4.6). 
• The concomitant use of Edarbi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Activated renin-angiotensin-aldosterone system (RAAS) </u></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the RAAS (e.g. patients with congestive heart failure, severe renal impairment or renal artery stenosis), treatment with medicinal products that affect this system, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with Edarbi.</p><p>Caution should be exercised in hypertensive patients with severe renal impairment, congestive heart failure or renal artery stenosis, as there is no experience of use of Edarbi in these patients (see sections 4.2 and 5.2).</p><p>Excessive blood pressure decreases in patients with ischaemic cardiomyopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p><u>Dual blockade of the RAAS </u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).&nbsp; If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><u>Kidney transplantation </u></p><p>There is currently no experience on the use of Edarbi in patients who have recently undergone kidney transplantation.</p><p><u>Hepatic impairment </u></p><p>Edarbi has not been studied in patients with severe hepatic impairment and therefore its use is not recommended in this patient group (see sections 4.2 and 5.2).</p><p><u>Hypotension in volume- and /or salt-depleted patients </u></p><p>In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Edarbi. Hypovolemia should be corrected prior to administration of Edarbi, or the treatment should start under close medical supervision, and consideration can be given to a starting dose of 20 mg.</p><p><u>Primary hyperaldosteronism </u></p><p>Patients with primary hyperaldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the RAAS. Therefore, the use of Edarbi is not recommended in these patients.</p><p><u>Hyperkalaemia </u></p><p>Based on experience with the use of other medicinal products that affect the RAAS, concomitant use of Edarbi with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin) may lead to increases in serum potassium in hypertensive patients (see section 4.5). In the elderly, in patients with renal insufficiency, in diabetic patients and/or in patients with other co-morbidities, the risk of hyperkalaemia, which may be fatal, is increased. Monitoring of potassium should be undertaken as appropriate.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy </u></p><p>Special caution is indicated in patients suffering from aortic or mitral valve stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><u>Pregnancy </u></p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Lithium </u></p><p>As with other angiotensin II receptor antagonists the combination of lithium and Edarbi is not recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use not recommended </u></p><p><em>Lithium </em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of lithium and angiotensin-converting enzyme inhibitors. A similar effect may occur with angiotensin II receptor antagonists. Due to the lack of experience with concomitant use of azilsartan medoxomil and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><u>Caution required with concomitant use </u></p><p><em>Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt; 3 g/day), and non-selective NSAIDs </em></p><p>When angiotensin II receptor antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II receptor antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, adequate hydration and monitoring of renal function at the beginning of the treatment are recommended.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels </em></p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of serum potassium should be undertaken as appropriate (see section 4.4).</p><p><u>Additional information </u></p><p>Clinical trial data has shown that dual blockade of the RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>No clinically significant interactions have been reported in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlortalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, and warfarin.</p><p>Azilsartan medoxomil is rapidly hydrolysed to the active moiety azilsartan by esterases in the gastrointestinal tract and/or during drug absorption (see section 5.2). <em>In vitro </em>studies indicated that interactions based on esterase inhibition are unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy Category: D.</p><p>The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4).</p><p>The use of angiotensin II receptor antagonists is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>There are no data from the use of azilsartan medoxomil in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to angiotensin converting enzyme inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there are no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of medicinal products. Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken Angiotensin II receptor antagonists should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><u>Breast-feeding </u></p><p>Because no information is available regarding the use of azilsartan medoxomil during breastfeeding, Edarbi is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while breast-feeding a newborn or preterm infant.</p><p><u>Fertility </u></p><p>No data are available on the effect of azilsartan medoxomil on human fertility. Nonclinical studies demonstrated that azilsartan did not appear to affect male or female fertility in the rat (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azilsartan medoxomil has no or negligible influence on the ability to drive and use machines. However it should be taken into account that occasionally dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>Edarbi at doses of 20, 40 or 80 mg has been evaluated for safety in clinical studies in patients treated for up to 56 weeks. In these clinical studies, adverse reactions associated with treatment with Edarbi were mostly mild or moderate, with an overall incidence similar to placebo. The most common adverse reaction was dizziness. The incidence of adverse reactions with this treatment was not affected by gender, age, or race. Adverse reactions were reported at a similar frequency for the Edarbi 20 mg dose as with the 40 and 80 mg doses in one placebo controlled study.</p><p><u>Tabulated list of adverse reactions </u></p><p>Adverse reactions based on pooled data (40 and 80 mg doses) are listed below according to system organ class and preferred terms. These are ranked by frequency, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), including isolated reports. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse reaction</strong></p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Dizziness</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Uncommon</p></td><td><p>Hypotension</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Common</p><p>Uncommon</p></td><td><p>Diarrhoea</p><p>Nausea</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Uncommon</p><p>Rare</p></td><td><p>Rash, pruritus</p><p>Angioedema</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Uncommon</p></td><td><p>Muscle spasms</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Uncommon</p></td><td><p>Fatigue</p><p>Peripheral oedema</p></td></tr><tr><td><p>Investigations</p></td><td><p>Common</p><p>&nbsp;</p><p>Uncommon</p></td><td><p>Blood creatine phosphokinase increased</p><p>&nbsp;</p><p>Blood creatinine increased</p><p>Blood uric acid increased / Hyperuricemia</p></td></tr></tbody></table><p><u>Description of selected adverse reactions </u></p><p>When Edarbi was coadministered with chlortalidone, the frequencies of blood creatinine increased and hypotension were increased from uncommon to common.</p><p>When Edarbi was coadministered with amlodipine, the frequency of peripheral oedema was increased from uncommon to common, but was lower than amlodipine alone.</p><p><u>Investigations</u></p><p><em>Serum creatinine </em></p><p>The incidence of elevations in serum creatinine following treatment with Edarbi was similar to placebo in the randomised placebo-controlled monotherapy studies. Coadministration of Edarbi with diuretics, such as chlortalidone, resulted in a greater incidence of creatinine elevations, an observation consistent with that of other angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors. The elevations in serum creatinine during coadminstiration of Edarbi with diuretics were associated with larger blood pressure reductions compared with a single medicinal product. Many of these elevations were transient or nonprogressive while subjects continued to receive treatment. Following discontinuation of treatment, the majority of the elevations that had not resolved during treatment were reversible, with the creatinine levels of most subjects returning to baseline or near-baseline values.</p><p><em>Uric acid </em></p><p>Small mean increases of serum uric acid were observed with Edarbi (10.8 &mu;mol/l) compared with placebo (4.3 &mu;mol/l).</p><p><em>Hemoglobin and hematocrit </em></p><p>Small decreases in hemoglobin and hematocrit (mean decreases of approximately 3 g/l and 1 volume percent, respectively) were observed in placebo-controlled monotherapy studies. This effect is also seen with other inhibitors of the RAAS.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms </em></p><p>Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic hypotension and dizziness. During controlled clinical studies in healthy subjects, once daily doses up to 320 mg of azilsartan medoxomil were administered for 7 days and were well tolerated.</p><p><em>Management </em></p><p>If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs monitored.</p><p>Azilsartan is not removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, plain, ATC Code: C09CA09</p><p><em><u>Mechanism of action </u></em></p><p>Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues (see section 5.2). Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.</p><p>Blockade of the AT1 receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increases in plasma renin activity and angiotensin II circulating levels do not overcome the antihypertensive effect of azilsartan.</p><p><em><u>Essential hypertension </u></em></p><p>In seven double blind controlled studies, a total of 5,941 patients (3,672 given Edarbi, 801 given placebo, and 1,468 given active comparator) were evaluated. Overall, 51% of patients were male and 26% were 65 years or older (5% &ge; 75 years); 67% were white and 19% were black.</p><p>Edarbi was compared with placebo and active comparators in two 6 week randomised, double blind studies. Blood pressure reductions compared with placebo based on 24 hour mean blood pressure by ambulatory blood pressure monitoring (ABPM) and clinic blood pressure measurements at trough are shown in the table below for both studies. Additionally, Edarbi 80 mg resulted in significantly greater reductions in SBP than the highest approved doses of olmesartan medoxomil and valsartan.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Edarbi 20 mg</strong></p></td><td><p><strong>Edarbi 40 mg#</strong></p></td><td><p><strong>Edarbi 80 mg# </strong></p></td><td><p><strong>OLM-M </strong></p><p><strong>40 mg#</strong></p></td><td><p><strong>Valsartan 320 mg#</strong></p></td></tr><tr><td colspan="7"><p><strong>Primary end point: </strong></p><p><strong>24 Hour Mean SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg)</strong></p></td></tr><tr><td colspan="7"><p><strong>Study 1</strong></p></td></tr><tr><td><p><strong>Change from BL</strong></p></td><td><p>-1.4</p></td><td><p>-12.2 *</p></td><td><p>-13.5 *</p></td><td><p>-14.6 *&dagger;</p></td><td><p>-12.6</p></td><td><p>-</p></td></tr><tr><td colspan="7"><p><strong>Study 2</strong></p></td></tr><tr><td><p><strong>Change from BL</strong></p></td><td><p>-0.3</p></td><td><p>-</p></td><td><p>-13.4 *</p></td><td><p>-14.5 *&dagger;</p></td><td><p>-12.0</p></td><td><p>-10.2</p></td></tr><tr><td colspan="7"><p><strong>Key Secondary End Point: </strong></p><p><strong>Clinic SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) (LOCF) </strong></p></td></tr><tr><td colspan="7"><p><strong>Study 1</strong></p></td></tr><tr><td><p><strong>Change from BL</strong></p></td><td><p>-2.1</p></td><td><p>-14.3 *</p></td><td><p>-14.5 *</p></td><td><p>-17.6 *</p></td><td><p>-14.9</p></td><td><p>-</p></td></tr><tr><td colspan="7"><p><strong>Study 2</strong></p></td></tr><tr><td><p><strong>Change from BL</strong></p></td><td><p>-1.8</p></td><td><p>-</p></td><td><p>-16.4 *&dagger;</p></td><td><p>-16.7 *&dagger;</p></td><td><p>-13.2</p></td><td><p>-11.3</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>OLM-M = olmesartan medoxomil, LS = least squares, LOCF = last observation carried forward</p><p>* Significant difference vs. Placebo at 0.05 level within the framework of the step-wise analysis</p><p>&dagger; Significant difference vs. Comparator(s) at 0.05 level within the framework of the step-wise analysis</p></td></tr><tr><td><p># Maximum dose achieved in study 2. Doses were force-titrated at Week 2 from 20 to 40 mg and 40 to 80 mg for Edarbi, and 20 to 40 mg and 160 to 320 mg, respectively, for olmesartan medoxomil and valsartan.</p></td></tr></tbody></table><p>In these two studies, clinically important and most common adverse events included dizziness, headache and dyslipidemia. For Edarbi, olmesartan medoxomil and valsartan, respectively dizziness was observed at an incidence of 3.0%, 3.3% and 1.8%; headache at 4.8%, 5.5% and 7.6% and dyslipidemia at 3.5%, 2.4% and 1.1%.</p><p>In active-comparator studies with either valsartan or ramipril, the blood-pressure-lowering effect with Edarbi was sustained during long-term treatment. Edarbi had a lower incidence of cough (1.2%) compared with ramipril (8.2%).</p><p>The antihypertensive effect of azilsartan medoxomil occurred within the first 2 weeks of dosing with the full effect achieved by 4 weeks. The blood pressure lowering effect of azilsartan medoxomil was also maintained throughout the 24 hour dosing interval. The placebo-corrected trough-to-peak ratios for SBP and DBP were approximately 80% or higher.</p><p>Rebound hypertension was not observed following abrupt cessation of Edarbi therapy after 6 months of treatment.</p><p>No overall differences in safety and effectiveness were observed between elderly patients and younger patients, but greater sensitivity to blood pressure lowering effects in some elderly individuals cannot be ruled out (see section 4.2). As with other angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors the antihypertensive effect was lower in black patients (usually a low-renin population).</p><p>Coadministration of Edarbi 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide-type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone. Dose dependent adverse events including dizziness, hypotension and serum creatinine elevations were more frequent with diuretic coadministration compared with Edarbi alone, while hypokalemia was less frequent compared with diuretic alone.</p><p>Beneficial effects of Edarbi on mortality and cardiovascular morbidity and target organ damage are currently unknown.</p><p><em><u>Effect on cardiac repolarisation </u></em></p><p>A thorough QT/QTc study was conducted to assess the potential of azilsartan medoxomil to prolong the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320 mg of azilsartan medoxomil.</p><p><em><u>Additional information </u></em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage.</p><p>VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><em><u>Paediatric population </u></em></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Edarbi in one or more subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, azilsartan medoxomil is rapidly hydrolyzed to the active moiety azilsartan in the gastrointestinal tract and/or during absorption. Based on <em>in vitro </em>studies, carboxymethylenebutenolidase is involved in the hydrolysis in the intestine and liver. In addition, plasma esterases are involved in the hydrolysis of azilsartan medoxomil to azilsartan.</p><p><u>Absorption </u></p><p>The estimated absolute oral bioavailability of azilsartan medoxomil based on plasma levels of azilsartan is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma concentrations (C<sub>max</sub>) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan (see section 4.2).</p><p><u>Distribution </u></p><p>The volume of distribution of azilsartan is approximately 16 litres. Azilsartan is highly bound to plasma proteins (&gt; 99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well above the range achieved with recommended doses.</p><p><u>Biotransformation </u></p><p>Azilsartan is metabolised to two primary metabolites. The major metabolite in plasma is formed by <em>O</em>-dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately 50% and less than 1% that of azilsartan, respectively. M-I and M-II do not contribute to the pharmacologic activity of azilsartan medoxomil. The major enzyme responsible for azilsartan metabolism is CYP2C9.</p><p><u>Elimination </u></p><p>Following an oral dose of <sup>14</sup>C-labelled azilsartan medoxomil, approximately 55% of radioactivity was recovered in faeces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 ml/min. Steady-state levels of azilsartan are achieved within 5 days and no accumulation in plasma occurs with repeated once-daily dosing.</p><p><u>Linearity/non-linearity </u></p><p>Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing.</p><p><u>Characteristics in specific groups of patients </u></p><p><em>Paediatric population </em></p><p>The pharmacokinetics of azilsartan have not been studied in children under 18 years of age.</p><p><em>&nbsp;Older people </em></p><p>Pharmacokinetics of azilsartan do not differ significantly between young (age range 18-45 years) and elderly (age range 65-85 years) patients.</p><p><em>&nbsp;Renal impairment </em></p><p>In patients with mild, moderate, and severe renal impairment azilsartan total exposure (AUC) was +30%, +25% and +95% increased. No increase (+5%) was observed in end-stage renal disease patients who were dialysed. However, there is no clinical experience in patients with severe renal impairment or end stage renal disease (see section 4.2). Hemodialysis does not remove azilsartan from the systemic circulation.</p><p><em>&nbsp;Hepatic impairment </em></p><p>Administration of Edarbi for up to 5 days in subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment resulted in slight increase in azilsartan exposure (AUC increased by 1.3 to 1.6 fold, see section 4.2). Edarbi has not been studied in patients with severe hepatic impairment.</p><p><em>&nbsp;Gender </em></p><p>Pharmacokinetics of azilsartan do not differ significantly between males and females. No dose adjustment is necessary based on gender.</p><p><em>&nbsp;Race </em></p><p>Pharmacokinetics of azilsartan do not differ significantly between black and white populations. No dose adjustment is necessary based on race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical safety studies, azilsartan medoxomil and M-II, the major human metabolite, were examined for repeated-dose toxicity, reproduction toxicity, mutagenicity and carcinogenicity.</p><p>In the repeated-dose toxicity studies, doses producing exposure comparable to that in the clinical therapeutic range caused reduced red cell parameters, changes in the kidney and renal haemodynamics, as well as increased serum potassium in normotensive animals. These effects, which were prevented by oral saline supplementation, do not have clinical significance in treatment of hypertension.</p><p>In rats and dogs, increased plasma renin activity and hypertrophy/hyperplasia of the renal juxtaglomerular cells were observed. These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical significance.</p><p>Azilsartan and M-II crossed the placenta and were found in the fetuses of pregnant rats and were excreted into the milk of lactating rats. In the reproduction toxicity studies, there were no effects on male or female fertility. There is no evidence of a teratogenic effect, but animal studies indicated some hazardous potential to the postnatal development of the offspring such as lower body weight, a slight delay in physical development (delayed incisor eruption, pinna detachment, eye opening), and higher mortality.</p><p>Azilsartan and M-II showed no evidence of mutagenicity and relevant clastogenic activity in <em>in vitro </em>studies and no evidence of carcinogenicity in rats and mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Mannitol</li><li>Fumaric acid</li><li>Sodium hydroxide</li><li>Hydroxypropylcellulose</li><li>Croscarmellose sodium</li><li>Microcrystalline cellulose&nbsp;</li><li>Magnesium stearate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum blisters.</p><p>Pack size: 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: jpimedical@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 September 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>